Targeted treatment for chronic lymphocytic leukemia

被引：5

作者：

Masood, Aisha ^{[2
]}

Sher, Taimur ^{[3
]}

Paulus, Aneel ^{[3
]}

Miller, Kena C. ^{[3
]}

Chitta, Kasyapa S. ^{[4
]}

Chanan-Khan, Asher ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol Oncol, Jacksonville, FL 32224 USA

[2] Mt Sinai Sch Med, Tisch Canc Inst, Bone Marrow Transplant Unit, New York, NY USA

[3] Roswell Pk Canc Inst, Dept Med, New York, NY USA

[4] Roswell Pk Canc Inst, Dept Mol Targets & Expt Therapeut, New York, NY USA

来源：

ONCOTARGETS AND THERAPY | 2011年 / 4卷

关键词：

CLL; Akt inhibitors; Bcl-2; inhibitors; cyclin d kinase inhibitors; heat shock protein inhibitors; immunomodulatory drugs; monoclonal antibodies; NON-HODGKINS-LYMPHOMA; FLUDARABINE PLUS CYCLOPHOSPHAMIDE; PHASE-I; INITIAL THERAPY; MONOCLONAL-ANTIBODY; UNTREATED PATIENTS; CLINICAL-EFFICACY; 1ST-LINE THERAPY; ANTI-CD20; MAB; CELL LYMPHOMA;

D O I：

10.2147/OTT.S7173

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The treatment of chronic lymphocytic leukemia (CLL) has evolved over the last few decades. Recognition has increased of several key components of CLL biology currently manipulated for therapeutics. A milestone in the treatment of CLL was reached with the incorporation of immunotherapy with conventional chemotherapy. The fludarabine/cyclophosphamide/rituximab combination has demonstrated survival advantage for the first time in the treatment of CLL. Several other biological compounds are being explored with the hope of improving responses, impacting survival, and ultimately curing CLL. Important agents being tested are targeted on CLL surface molecules and their ligands, signal transduction protein and oncogenes. This review provides a brief summary of the recent advances made in preclinical and clinical investigation of selected promising therapeutic agents, which lead the target-directed therapeutic approach.

引用

页码：169 / 183

页数：15

共 50 条

[41] The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy [J].

Nastoupil, Loretta J. ;

Sinha, Rajni ;

Flowers, Christopher R. .

EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (09) :1089-1108

[42] Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia [J].

Pepe, Felice ;

Balatti, Veronica .

JOURNAL OF CLINICAL MEDICINE, 2020, 9 (02)

[43] Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy [J].

Small, Sara ;

Ma, Shuo .

CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2021, 16 (04) :325-335

[44] Emerging immunological drugs for chronic lymphocytic leukemia [J].

Robak, Pawel ;

Smolewski, Piotr ;

Robak, Tadeusz .

EXPERT OPINION ON EMERGING DRUGS, 2015, 20 (03) :423-447

[45] The future of antibody therapy in chronic lymphocytic leukemia [J].

Crombie, Jennifer L. ;

Brown, Jennifer R. .

EXPERT OPINION ON EMERGING DRUGS, 2021, 26 (03) :323-336

[46] BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia [J].

Perini, Guilherme Fleury ;

Pellegrino Feres, Carolina Cristina ;

Cardoso Teixeira, Larissa Lane ;

Hamerschlak, Nelson .

CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2021, 22 (08)

[47] Targeted Therapy in Chronic Lymphocytic Leukemia (CLL) [J].

Pettijohn, Erin M. ;

Ma, Shuo .

CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2017, 12 (01) :20-28

[48] Progress in Chronic Lymphocytic Leukemia with Targeted Therapy [J].

Wilson, Wyndham H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (04) :386-388

[49] Towards Targeted Therapy of Chronic Lymphocytic Leukemia [J].

Niemann, Carsten U. ;

Jones, Jade ;

Wiestner, Adrian .

ADVANCES IN CHRONIC LYMPHOCYTIC LEUKEMIA, 2013, 792 :259-291

[50] Treatment of Chronic Lymphocytic Leukemia [J].

Burger, Jan A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (05) :460-473

← 1 2 3 4 5 →